Adcock Ingram Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Adcock Ingram Limited Pharmaceutical Export Portfolio Dataset — 13 Products, $98.8M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Adcock Ingram Limited — Pharmaceutical Exporter Profile (2026) | 13 Products, $98.8M Trade | TransData Nexus

Adcock Ingram Limited

Indian Pharmaceutical Exporter · Analgesics & Antipyretics Specialist · $98.8M Total Trade · DGFT Verified

Adcock Ingram Limited is an Indian pharmaceutical exporter with a total trade value of $98.8M across 13 products in 7 therapeutic categories. Based on 4,011 verified export shipments from Indian Customs (DGFT) records, Adcock Ingram Limited is the #1 Indian exporter in 2 products including Paracetamol, Caffeine. Top exports include Codeine ($33.3M), Paracetamol ($27.7M), Caffeine ($22.3M).

Adcock Ingram Limited — Export Portfolio & Destination Treemap

Adcock Ingram Limited pharmaceutical export portfolio — 13 products across 7 therapeutic categories. Source: Indian Customs (DGFT).

Who is Adcock Ingram Limited? — Company Overview & Market Position

Adcock Ingram Limited, incorporated on April 3, 2007, is a public unlisted company based in Bengaluru, Karnataka, India. Its Corporate Identification Number (CIN) is U24232KA2007PLC042361. The company is primarily engaged in the manufacturing of chemicals and chemical products, focusing on finished pharmaceutical formulations such as tablets, capsules, syrups, and injections.

As of the latest available data, Adcock Ingram Limited has an authorized capital of ₹400 million and a paid-up capital of ₹380.5 million. The company's registered office is located at Plot No. 49 D, Bommasandra Industrial Area, Anekal Taluk, Bengaluru, Karnataka, 560099, India.

In August 2023, Chandra Mohan was appointed as the Chief Financial Officer (CFO), bringing over two years of experience with the company.

What Does Adcock Ingram Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Codeine$33.3M 2Paracetamol

Product Portfolio — Top 13 by Export Value

Adcock Ingram Limited exports 13 pharmaceutical products across 7 therapeutic categories. Market leader (#1 exporter) in 2 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Codeine	Analgesics & Antipyretics	$33.3M	964	30.5%	2
2	Paracetamol	Analgesics & Antipyretics	$27.7M	1,127	7.8%	1
3	Caffeine	Respiratory & OTC	$22.3M	759	20.7%	1
4	Ibuprofen	Analgesics & Antipyretics	$5.5M	357	0.9%	15
5	Theophylline	Respiratory	$3.0M	98	17.0%	2
6	Chlorpheniramine	Antihistamines & Allergy	$2.6M	292	5.7%	3
7	Aspirin	Analgesics & Antipyretics	$1.9M	138	5.1%	4
8	Atenolol	Cardiovascular	$953.7K	101	2.3%	9
9	Metoclopramide	Gastrointestinal	$536.0K	105	2.4%	6
10	Allopurinol	Lipid & Metabolism	$467.3K	27	0.1%	13
11	Bromhexine	Respiratory & OTC	$269.6K	16	1.7%	12
12	Bisacodyl	Gastrointestinal	$214.6K	23	2.5%	10
13	Docusate	Gastrointestinal	$134.6K	4	1.5%	7

Adcock Ingram Limited exports 13 pharmaceutical products across 7 therapeutic categories with a total export value of $98.8M. The company is the #1 Indian exporter in 2 products: Paracetamol, Caffeine. The top category is Analgesics & Antipyretics (69.2% of portfolio), followed by Respiratory & OTC (22.8%), indicating a concentrated portfolio with the top 5 products accounting for 92.8% of total export value.

Adcock Ingram Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

In August 2023, Chandra Mohan was appointed as the Chief Financial Officer (CFO), bringing over two years of experience with the company.

2Manufacturing Facilities

Adcock Ingram Limited operates a manufacturing facility situated in the Bommasandra Industrial Area of Bengaluru, Karnataka. This plant specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The facility is strategically located to serve both domestic and international markets, ensuring efficient distribution and compliance with regulatory standards.

3Key Leadership

The leadership team at Adcock Ingram Limited is headed by Chandra Mohan, who assumed the role of Chief Financial Officer (CFO) in August 2023. His appointment reflects the company's commitment to strengthening its financial management and strategic direction. The board of directors includes Pravin Vaidyanathan Iyer, Alok Sharma, Pankaj Garg, Yasuhiro Nakagiri, and others, each bringing diverse expertise to the company's governance.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Adcock Ingram Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Adcock Ingram Limited's export portfolio, valued at $98.8 million USD over 4,011 shipments, includes 13 products across seven therapeutic categories. Notably, the company holds the number one market position in Paracetamol and Caffeine, with market shares of 7.8% and 20.7%, respectively. These products are essential in the analgesics and antipyretics category, which constitutes 69.2% of their export value. The company's strong presence in regulated markets underscores its adherence to international quality standards and regulatory requirements.

2Emerging Markets

Adcock Ingram Limited's strategic focus on emerging markets is evident through its significant export activities in regions such as Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards has facilitated access to these markets, enabling it to offer a range of pharmaceutical products that meet international quality benchmarks. This approach not only broadens the company's market reach but also contributes to improving healthcare access in these regions.

3Geographic Strategy

Adcock Ingram Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of the latest available data, Adcock Ingram Limited has not reported any FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), or Drug Master File (DMF) filings. The company has not been subject to any FDA Form 483 observations, warning letters, or import alerts. This indicates that Adcock Ingram Limited has not pursued market access in the United States, focusing its efforts on other international markets.

2WHO & EU GMP

Adcock Ingram Limited's commitment to quality is demonstrated by its adherence to WHO prequalification standards, facilitating access to various international markets. The company holds EU Good Manufacturing Practice (GMP) certificates, ensuring that its manufacturing processes meet the stringent requirements set by the European Directorate for the Quality of Medicines & HealthCare (EDQM). These certifications underscore the company's dedication to producing high-quality pharmaceutical products.

3CDSCO & Indian Regulatory

Adcock Ingram Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the analgesics and antipyretics category, Adcock Ingram Limited faces competition from other pharmaceutical companies with established market presence. However, the company's leadership in Paracetamol and Caffeine, with market shares of 7.8% and 20.7%, respectively, positions it favorably in the global market. The high concentration of exports in these top products indicates a strong competitive edge, though it also suggests potential vulnerabilities to market dynamics and regulatory changes.

2Key Differentiators

Adcock Ingram Limited's key differentiators include its strong market position in Paracetamol and Caffeine, adherence to international quality standards such as WHO prequalification and EU GMP certifications, and a diversified export portfolio across multiple therapeutic categories. These factors contribute to the company's competitive advantage in the global pharmaceutical market.

3Strategic Position

Adcock Ingram Limited's current strategic direction focuses on the production and export of finished pharmaceutical formulations, with a significant emphasis on analgesics and antipyretics. The company's adherence to international quality standards and its strong presence in emerging markets reflect a commitment to expanding its global footprint. Future strategic initiatives may include diversifying the product portfolio, exploring new therapeutic areas, and enhancing market penetration in regulated markets to mitigate risks associated with product concentration.

Buyer Due Diligence Brief — Evaluating Adcock Ingram Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Adcock Ingram Limited has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products, with a total export value of $98.8 million USD over 4,011 shipments. The company's adherence to international quality standards, as evidenced by its WHO prequalification and EU GMP certifications, indicates a high level of reliability. The concentration of exports in top products suggests a focused approach, though it also highlights the importance of diversifying the product portfolio to enhance resilience.

2Certifications to Verify

Importers should verify the following certifications when considering Adcock Ingram Limited as a supplier:

WHO Prequalification: Confirms that the company's products meet international quality standards. Verification can be done through the WHO's official website.

EU GMP Certificates: Indicate compliance with European manufacturing standards. These certificates can be verified through the European Medicines Agency (EMA).

Frequently Asked Questions — Adcock Ingram Limited

How many pharmaceutical products does Adcock Ingram Limited export from India?

Adcock Ingram Limited exports 13 pharmaceutical products across 7 therapeutic categories. The top exports are Codeine ($33.3M), Paracetamol ($27.7M), Caffeine ($22.3M), Ibuprofen ($5.5M), Theophylline ($3.0M). Total export value is $98.8M.

What is Adcock Ingram Limited's total pharmaceutical export value?

Adcock Ingram Limited's total pharmaceutical export value is $98.8M, based on 4,011 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Adcock Ingram Limited the #1 Indian exporter?

Adcock Ingram Limited is the #1 Indian exporter in 2 products: Paracetamol (7.8% market share), Caffeine (20.7% market share).

What therapeutic categories does Adcock Ingram Limited cover?

Adcock Ingram Limited exports across 7 therapeutic categories. The largest are Analgesics & Antipyretics (69.2%, 4 products), Respiratory & OTC (22.8%, 2 products), Respiratory (3.0%, 1 products).

Get Full Adcock Ingram Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.